학술논문

Window of opportunity trial of neoadjuvant olaparib and durvalumab for triple negative or low ER-positive breast cancer
Document Type
Journal
Source
CANCER RESEARCH; FEB 15 2022, 82 4, 3p. Supplement: S
Subject
Language
English
ISSN
15387445